Shown: posts 1 to 6 of 6. This is the beginning of the thread.
Posted by iforgotmypassword on October 27, 2006, at 0:36:40
Tolcapone Improves Cognition and Cortical Information Processing in Normal Human Subjects.
it helps normal people, imagine what it might do for us folx. executive function is a huge weakness for me. i worry seriously about cholinergic and anterior cingulate function in me though, being a hoarder. if they are serious about it being non-stimulant though, it is very tempting.
if it helps normal people, will that impede it ever being released? is it on queue for passing any FDA approval stages for anything?
Posted by iforgotmypassword on October 27, 2006, at 0:41:58
In reply to Tolcapone Improves Cognition and Cortical Informat, posted by iforgotmypassword on October 27, 2006, at 0:36:40
i hope it wasn't over wonky hooplah as with nefazodone (serzone) and pemoline (cylert).
annoying. they should experiment with other COMT inhibitors big time.
Posted by ed_uk on October 27, 2006, at 14:52:54
In reply to Tolcapone Improves Cognition and Cortical Informat, posted by iforgotmypassword on October 27, 2006, at 0:36:40
Entacapone is a similar drug to tolcapone, without the liver damage. Entacapone is marketed as an adjunct in the treatment of Parkinson's disease.
Ed
Posted by zeugma on October 27, 2006, at 17:32:03
In reply to Re: Tolcapone Improves Cognition and Cortical Informat, posted by ed_uk on October 27, 2006, at 14:52:54
yes, but entacapone is useless for psychotropic purposes, because it doesm't cross the blood-brain barrier.
-z
Posted by ed_uk on October 29, 2006, at 10:25:06
In reply to Re: Tolcapone Improves Cognition and Cortical Informat » ed_uk, posted by zeugma on October 27, 2006, at 17:32:03
I didn't know that Z.
Thanks
Ed
Posted by zeugma on October 29, 2006, at 16:24:48
In reply to Re: Tolcapone Improves Cognition and Cortical Informat » zeugma, posted by ed_uk on October 29, 2006, at 10:25:06
you're welcome Ed.
it is unfortunate that there are no non-hepatoxic COMT inhibitors in the pipeline anwhere, as far as I can can tell. Many European countries are critical of the FDA's choice to bring tolcapone back to the market, because entapocone, despite its lack of BBB penetration, works just as well in augmenting L-Dopa in Parkinson's patients. I wish pharmacagenetic research- which shows that COMT genotype significantly affects the response to atypical antipsychotics as well as to stimulants- would be taken more seriously by the drug companies, which might spur them to develop a centrally acting and safer COMT inhibitor.
-z
This is the end of the thread.
Psycho-Babble Medication | Extras | FAQ
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.org
Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.